HAYWARD, Calif., March 22, 2013 /PRNewswire/ –?Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its…
Here is the original post:
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
CAMBRIDGE, Mass., March 22, 2013 /PRNewswire/ — Cerulean Pharma Inc. today announced that a randomized Phase 2b study of its experimental cancer treatment, CRLX101, in patients with advanced non-small cell lung cancer (NSCLC) did not meet its…
See more here:
Cerulean Announces Results from Phase 2b Lung Cancer Trial
– In more than 70 percent of patients, disability scores improved or remained stable over three years — – More than 80 percent of patients treated with LEMTRADA did not receive a third course of treatment in the first year of the extension…
Go here to read the rest:
Effect of Genzyme’s Lemtrada Maintained in Patients Beyond Two-Year Pivotal MS Studies
- Lymphoseek Meets Primary Efficacy Endpoint in Assessment of Lymphatic Mapping Performance in Patients with Breast Cancer – DUBLIN, Ohio–(BUSINESS WIRE)–Mar 21, 2013 – Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company…
See original here:
Results of Lymphoseek Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology
Isis to host an investor event and live webcast at 7:30 am PT on Thursday, March 21 in San Diego ? CARLSBAD, Calif., March 20, 2013 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of…
Read this article:
Data From ISIS-SMN Rx Phase 1 Study in Children With Spinal Muscular Atrophy Presented at the American Academy of Neurology Meeting
Demonstrates Weight Maintenance and Increase in Patient Appetite and Quality Of Life ? NEW YORK, March 21, 2013 /PRNewswire/ — Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for…
Go here to read the rest:
Ohr Pharmaceutical Announces Results from OHR/AVR118 Phase II Trial in Cancer Cachexia
SAN DIEGO–(BUSINESS WIRE)–Mar 21, 2013 – ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system…
See the rest here:
ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of…
Anacor Will Host a Conference Call Today 8am ET / 5am PT to Discuss Results PALO ALTO, Calif.–(BUSINESS WIRE)–Mar 21, 2013 – Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of…
See the rest here:
Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic Dermatitis
Data presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) showed early treatment with laquinimod demonstrated significant benefit in terms of slowing disability progression compared to delayed treatment 36-month data…
| © 2011 MSL WORLD |